From description to prediction
Sequencing alone describes biology; paired with functional response, it predicts it. We connect mutational and expression profiles to measured ex vivo drug sensitivity to surface candidate biomarkers and mechanisms.
A sequencing and transcriptomics add-on, including targeted NGS, whole-exome, whole-genome, and bulk or single-cell RNA-seq, integrated with ex vivo drug-response data.
Sequencing alone describes biology; paired with functional response, it predicts it. We connect mutational and expression profiles to measured ex vivo drug sensitivity to surface candidate biomarkers and mechanisms.
Targeted NGS panels, whole-exome (WES), and whole-genome (WGS) — with mutation summary, gene list, variant allele frequency, and predicted impact.
Bulk RNA-seq andsingle-cell RNA-seq with pathway analysis, cluster identification, and UMAPvisualization.
Genotype and expression correlated with drug response to generate predictive-biomarker and enrichment hypotheses.
Pairs with any live-cell service and the natural companion to Biomarker Validation and Drug-Resistance Profiling.
Key Deliverables
A scientist — not a sales desk — will scope a tailored study and return a design and timeline.
